Skip to main content
S&P 5007,688.62+1.58%DOW53,356.12+3.03%NASDAQ25,736.51+1.44%BTC$80,683.00+3.69%ETH$2,436.19+6.33%GOLD$4,072.20-0.02%OIL$88.04-0.09%
Smart Investors Daily
SID Premium
DN

NASDAQ · DNTH

Dianthus Therapeutics, Inc.

Healthcare · Biotechnology

$82.70

Up+$3.11 (+3.76%)

Updated Nov 4, 2026, 11:01 PM

SID Score

4.3/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
1.51B
P/E ratio
-12.45
Dividend yield
0.00%
52-week range
$68.85 – $117.88
Volume
1.53M
Avg. volume
657.86K

Price performance · DNTH

DNTH price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Nov 3, 2026

DNTH closed at $82.70 after 21 trading sessions, down 3.16% for the selected period.

Last close
$82.70
Period change
-3.16%
Period low
$72.09
Period high
$85.40
Daily close
View OHLC price history
DNTH OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Nov 3, 2026$83.21$86.17$81.57$82.701.53M
Nov 2, 2026$82.46$84.56$80.75$82.25837.8K
Oct 30, 2026$81.29$83.73$80.575$82.38496.89K
Oct 29, 2026$82.87$84.6959$81.875$82.70849.06K
Oct 28, 2026$77.82$82.45$77.26$82.31658.44K
Oct 27, 2026$79.55$81.10$78.64$79.52748.69K
Oct 26, 2026$77.87$79.90$77.05$79.33501.18K
Oct 23, 2026$76.03$78.155$76.02$76.78379.23K
Oct 22, 2026$77.13$78.96$75.40$78.531.48M
Oct 21, 2026$78.89$80.7411$77.26$78.101.19M
Oct 20, 2026$74.61$79.93$73.165$78.751.87M
Oct 19, 2026$73.55$76.04$72.125$74.54972.52K
Oct 16, 2026$74.41$75.3435$69.43$72.091.05M
Oct 15, 2026$75.77$77.55$72.67$74.53943.58K
Oct 14, 2026$77.17$78.78$74.47$74.76977.33K
Oct 13, 2026$81.42$81.46$77.25$77.581.32M
Oct 12, 2026$81.77$83.765$80.91$81.57853.95K
Oct 9, 2026$82.36$85.20$82.13$82.37738.87K
Oct 8, 2026$84.73$84.85$81.06$82.431M
Oct 7, 2026$84.60$86.61$84.13$84.88562.47K
Oct 6, 2026$88.58$88.58$83.185$85.401.35M

Latest DNTH news

The latest Smart Investors Daily articles mentioning DNTH.

Stock researchCompany · Overview

DNTH research

Overview

Company profile and research snapshot.

Company profile

Dianthus Therapeutics Inc is a clinical-stage biotechnology company dedicated to designing and delivering novel, monoclonal antibodies with improved selectivity and potency over existing complement therapies. The company is focused on developing next-generation complement therapeutics for patients living with severe autoimmune and inflammatory diseases. The company is comprised of an experienced team of biotech and pharma executives. The company's pipeline consists of DNTH103 a subcutaneous active C1s antibody.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$67.25
Implied upside
—
Analysts
—
DNTH recent ratings
DateFirmRatingTarget
Oct 27, 2026Roth CapitalBuy—
Oct 15, 2026HC Wainwright & Co.Buy—
Sep 11, 2026JP MorganOverweight—
Sep 4, 2026CitigroupBuy—
Aug 6, 2026Truist SecuritiesBuy—
Open full forecast

News briefing

Generated Nov 4, 2026, 9:19 PM

Why Is DNTH Up Today?

Dianthus Therapeutics shares gained 3.73% today as the company continues executing its investor engagement strategy heading into year-end. While the recent headlines lack major clinical or commercial catalysts, the stock's modest appreciation reflects steady institutional positioning and the company's proactive approach to market communication.

    Bottom line: DNTH's modest daily gain appears to be more about investor relations execution and market positioning than transformative business news. Investors should view today's movement as a neutral-to-bullish sign of management engagement while remaining vigilant for actual clinical progress or partnership announcements that would justify longer-term conviction in the stock.

    Yahoo · Nov 2, 2026

    Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    NEW YORK and WALTHAM, Mass., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to developing next-generation therapies to transform the treatment of severe autoimmune diseases, today announced that it granted equity awards on November 2, 2026, to three newly-hired, non-executive employees. The inducement grants were approved by the Company's independent Compensation Committee and were made as material inducements to acc

    Yahoo · Nov 2, 2026

    Dianthus Therapeutics to Participate in Five Investor Conferences During November

    NEW YORK and WALTHAM, Mass., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to developing next-generation therapies to transform the treatment of severe autoimmune diseases, today announced the Company’s participation in five investor conferences. Guggenheim 3rd Annual Healthcare Innovation Conference: Marino Garcia, CEO, will participate in a fireside chat on Monday, November 9, 2026, at 11:00 a.m. ET. Marino Garcia

    AI research layers

    Interpretive context generated from the platform’s current data sources.

    No results

    AI research layers have not been published yet.

    Featured By